openPR Logo
Press release

Dravet Syndrome Treatment Market - Global Industry Insights, 2026

07-05-2018 03:58 PM CET | Health & Medicine

Press release from: Coherent Market Insights

Dravet Syndrome Treatment Market - Global Industry Insights,

Dravet syndrome (DS), also known as epilepsy with polymorphic seizures and polymorphic epilepsy in infancy (PMEI), is a severe and rare genetic dysfunction of the brain (epileptic encephalopathy). It usually begins in first year of life and remains throughout lifetime. Children suffering from dravet syndrome suffer from different type of seizures namely, myoclonic seizures, tonic-clonic seizures, absence seizures, atypical absence seizures, atonic seizures, focal aware or impaired awareness seizures (previously called partial seizures), and status epilepticus. Generally, combination of drugs are prescribed for the treatment of Dravet syndrome. Anticonvulsants such as stiripentol, topiramate, and Valproic acid are the most commonly used drugs for treatment of seizures and Dravet syndrome. In cases where intensity of seizures are not reduced by medication, certain devices are used to treat Dravet syndrome. Vagal nerve stimulation device is one such device, which delivers electrical impulses to the vagus nerve.

Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/1548

Dravet Syndrome Treatment Market Drivers

Increasing research & development activities for the development of novel drugs for Dravet syndrome, and subsequently their approval in key regions such as North America and Europe is expected to fuel growth of the global Dravet syndrome treatment market in near future. In 2017, Epygenix Therapeutics, Inc.—a biopharmaceutical company—received U.S. Food and Drug Administration (FDA) orphan drug designation for its EPX-300, indicated for the treatment of Dravet syndrome. In 2017, Ovid Therapeutics—a U.S.-based biopharmaceutical company—received orphan drug designation for TAK-935/OV935 by U.S. Food and Drug Administration (FDA). In February 2018, Zogenix Inc. announced FDA approval of breakthrough therapy designation to ZX-008, its Phase III drug for seizures associated with Dravet Syndrome. In 2017, OPKO Pharmaceuticals LLC, a subsidiary of OPKO Health, Inc., received orphan drug designation from U.S. FDA for its oligonucleotide-based AntagoNAT (CUR-1916) indicated for the treatment of Dravet Syndrome, and the company also received orphan drug designation for its CUR-1916 from European Commission during the same year. Furthermore, strategic collaborations among key players in market for the development and manufacturing of drugs indicated for treatment of Dravet syndrome is also expected to drive growth of the Dravet syndrome treatment market. For instance, in 2017, Laurus Synthesis Inc. and Epygenix Therapeutics, Inc., entered into a strategic collaboration for development and manufacture of EPX-100. Under the agreement, Laurus Synthesis will provide chemistry development services and manufacturing in support of an upcoming clinical trial for EPX-100 for adolescents suffering from Dravet syndrome. In 2017, Takeda Pharmaceutical Company Limited entered into a global collaboration agreement with Ovid for development and commercialization of TAK-935/OV935 for the treatment of developmental and epileptic encephalopathies.

Dravet Syndrome Treatment Market Regional Analysis

North America is expected to a hold dominant position in the global Dravet syndrome treatment market, owing to increasing initiatives and funding by various organizations to support the development of new treatment for Dravet syndrome. For instances, in 2017, The Dravet Syndrome Foundation—a U.S.-based non-profit organization dedicated to funding the highest caliber research on Dravet syndrome—funded a total amount of US$ 3,600,000 for the development of novel treatment methods for Dravet syndrome. In 2011, Dravet Syndrome Foundation granted an undisclosed amount to U.S.-based OPKO Health, Inc., to support the company's efforts to develop potential therapeutic agents for the treatment of Dravet syndrome. The market in Europe is expected to exhibit significant growth in the Dravet syndrome treatment market, owing to increasing research and development activities being adopted by key players present in the region. For instance, GW Pharmaceuticals, a British biopharmaceutical company, developed Epidiolex (cannabidiol) based on an ingredient derived from marijuana. The company submitted new drug application (NDA) to the U.S. FDA for Epidiolex, in December 2017. If approved by the FDA, Epidiolex is expected to enter the market in the U.S. by mid of 2018.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/dravet-syndrome-treatment-market-1548

Dravet Syndrome Treatment Market Restraint

According to a study published in NCBI in 2015, the dravet syndrome affects only around 1 out of 15,700 individuals in the U.S. The prevalence of dravet syndrome is so rare that most of the population do not have much knowledge about it which is the major factor restraining the dravet syndrome market growth.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Blog: https://globalresearchtrends.blogspot.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Dravet Syndrome Treatment Market - Global Industry Insights, 2026 here

News-ID: 1112255 • Views: 343

More Releases from Coherent Market Insights

Colostrum Market Grow at a CAGR of 4 % Forecast to 2027 | APS Biogroup, Biostrum …
Colostrum is the first milk produced by newborn humans, cows, and other mammals. It is nutrient-dense and contains antibodies, which are necessary for infants and newborn animals to fight infections and grow normally.The most recent research on the global "Colostrum Market" provides a comprehensive overview of the factors that influence the global business landscape. Up-to-date market insights, current situation analysis with upcoming trends, and a breakdown of products and services
Magnesium Oxide Market Grow at 4.16% CAGR Between 2019 and 2027 | Martin Mariett …
Magnesium oxide, also known as magnesia, is a chemical compound with numerous applications.The most recent research on the global "Magnesium Oxide Market" provides a comprehensive overview of the factors that influence the global business landscape. Up-to-date market insights, current situation analysis with upcoming trends, and a breakdown of products and services are all included in Magnesium Oxide market research reports. Key statistics on Magnesium Oxide market conditions, size, share, and
Fine Hydrate Market Is Expected To Reach USD 550 million by 2027 | Nabaltec AG, …
Fine hydrate is a non-halogenated flame retardant additive used in injection moulding, wire and cable compounds, and paints and polymers, among other applications.The most recent research on the global "Fine Hydrate Market" provides a comprehensive overview of the factors that influence the global business landscape. Up-to-date market insights, current situation analysis with upcoming trends, and a breakdown of products and services are all included in Fine Hydrate market research reports.
GCC Lubricant Packaging Market Growth with 3.3 % CAGR Predicted till 2019-2027 | …
Lubricant packaging is used to store lubricants so that they can maintain their properties for a set period of time.The most recent research on the global "GCC Lubricant Packaging Market" provides a comprehensive overview of the factors that influence the global business landscape. Up-to-date market insights, current situation analysis with upcoming trends, and a breakdown of products and services are all included in GCC Lubricant Packaging market research reports. Key

All 5 Releases


More Releases for Dravet

Dravet Syndrome Treatment Market Global Industry Demand, Recent Trends, Size and …
Dravet syndrome is a distressing infantile-onset epilepsy, which is sometimes accompanied by severe intellectual disabilities, autistic traits, hyperactive behavior, and ataxia. Discovery of SCN1A mutation in 2001 as a primary cause of this syndrome has accelerated the knowledge of the pathophysiological processes behind Dravet syndrome. View Report : https://www.transparencymarketresearch.com/dravet-syndrome-treatment-market.html SCN1A is responsible for encoding the ?-subunit of the voltage-gated sodium channel NaV1.1. Recent studies, using genetically modified mouse models, have indicated
Dravet Syndrome Therapeutics- Pipeline Analysis 2018 | Zogenix, Inc., Ovid Thera …
Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus. Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity. Download the sample report @ https://www.pharmaproff.com/request-sample/1098 It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due
Dravet Syndrome Treatment Market Trends in 2019- What Industry Insiders Tell Us …
MarketResearchReports.Biz announces addition of new report "Dravet Syndrome Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026" to its database. Dravet syndrome is a distressing infantile-onset epilepsy, which is sometimes accompanied by severe intellectual disabilities, autistic traits, hyperactive behavior, and ataxia. Discovery of SCN1A mutation in 2001 as a primary cause of this syndrome has accelerated the knowledge of the pathophysiological processes behind Dravet syndrome.
Dravet Syndrome Treatment Market - Substantial Rise in Industrial Sectors to Off …
The newly released research at Up Market Research titled “2019 - 2025 Global Dravet Syndrome Treatment Market Report” provides data, information, brief analysis, company profiles, statistics for past years and forecasts for next few years. This report presents a comprehensive overview, market shares, and growth opportunities of Dravet Syndrome Treatment Market by product type, application, key manufacturers and key regions. Request Sample Copy Of this Report @ https://www.upmarketresearch.com/home/requested_sample/77681 Dravet Syndrome Treatment
2023 Dravet Syndrome Market Players Adopting to Ensure Sustainability | Biocodex …
Market Research Future recently presented Global Dravet Syndrome Market study with detailed review, portraying about the Product/Industry Scope and expounds market outlook and status to 2023. Dravet Syndrome Market - Highlights Dravet Syndrome is a severe form of the epileptic disorder that initiates in the first year of an otherwise healthy infant. Around 85% of children with Dravet syndrome develop myoclonic seizures between 1-5 years. Many factors such as the development of new
Global Dravet Syndrome Treatment Market Status, Share, Significant Trends, Drive …
An up-to-date research report has been disclosed by Market Research Hub highlighting the title “Global Dravet Syndrome Treatment Market Insights, Forecast to 2025” which provides an outlook for current market value as well as the expected growth of Dravet Syndrome Treatment Market during 2018-2025. The report studies the casing heads market worldwide, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, size, growth, revenue, consumption, import